Merck’s Pipeline Progress and Oncology Strength Drive Sales Growth Amid Acquisition-Related Charges

Broad-Based Sales Growth Powered by Oncology and Animal Health

Merck & Co., Inc. kicked off 2026 by advancing both its portfolio and pipeline. The company's total worldwide sales reached $16.3 billion in the first quarter, a 5% increase versus the prior year, driven by strong performances in Oncology and Animal Health, as well as contributions from newly launched products.

Oncology remains a cornerstone of Merck’s growth. KEYTRUDA (including KEYTRUDA QLEX) delivered revenues of $8.0 billion, soaring 12% year-over-year as usage expanded in both metastatic and earlier-stage cancer indications. WINREVAIR also logged an impressive 88% sales jump to $525 million, reflecting successful international launches and growing uptake in major markets.

Animal Health revenue climbed 13% year-over-year, reaching $1.8 billion. This reflects robust demand for both livestock and companion animal products, with the BRAVECTO line alone seeing 16% growth.

Acquisition-Related Charges Temporarily Weigh on Profitability

Despite sales momentum, Merck reported a GAAP loss per share of $1.72 and a non-GAAP loss per share of $1.28 for the quarter. This was primarily the result of a $3.62 per share charge linked to its acquisition of Cidara. Such charges contributed to a non-GAAP net loss of $3.16 billion for the quarter, compared to a $5.6 billion profit a year ago.

R&D spending surged, totaling $12.6 billion including the one-time charge. Even so, gross margins remained robust on a non-GAAP basis at nearly 82%, hinting at operational resilience once these transient costs cycle through.

Regulatory Milestones and Pipeline Advancements Signal Ongoing Momentum

Merck notched multiple regulatory wins and advanced several late-stage programs this quarter. Highlights include:

• FDA approval of IDVYNSO, a once-daily oral treatment for certain HIV-1 patients.
• Multiple priority reviews and approvals for KEYTRUDA regimens in ovarian and bladder cancer indications—some with PDUFA dates as soon as June and August 2026.
• Positive data for new uses of WINREVAIR, as well as progress in RSV prevention for infants and children with ENFLONSIA.
• Imminent acquisition of Terns Pharmaceuticals, set to further expand Merck’s hematology pipeline.

Looking further ahead, management is focused on a diverse pipeline. Recent partnerships with Mayo Clinic (for AI-driven drug discovery) and Google Cloud underscore Merck’s commitment to next-generation R&D.

Raised Full-Year Outlook Reaffirms Confidence in Diversified Growth

Buoyed by strong first-quarter results and pipeline momentum, Merck raised the midpoint of its full-year 2026 sales outlook to $66.4 billion (range: $65.8B–$67.0B) and expects non-GAAP EPS between $5.04 and $5.16, even as these figures incorporate the one-time Cidara charge. Notably, this forecast does not yet account for the pending Terns Pharmaceuticals deal, which is expected to close in May and trigger another one-time charge of approximately $5.8 billion.

Investor Takeaways: Resilient Core, Transformative Pipeline

For investors and followers of the pharmaceutical sector, Merck’s first quarter highlights the trade-offs of transformative pipeline investment and strategic acquisitions. While headline EPS figures are deep in the red this quarter, underlying sales strength and a diverse late-stage pipeline—with more than half a dozen regulatory decisions looming in the months ahead—paint a picture of a company on the offense, not the defensive.

With oncology and animal health serving as reliable growth engines, new launches gaining traction, and innovation spanning from cancer to cardiometabolic diseases and animal health, Merck is reinforcing its long-term strategy. The raised outlook reflects this confidence—even if the bottom line remains noisy in the near term due to aggressive investment in its future portfolio expansion.

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI